玉屏风胶囊联合舒利迭对咳嗽变异性哮喘的免疫调节作用研究  

The immunoregulation and clinical effect of Yupingfeng capsule combined with Seretide on patients with cough variant asthma

作　　者：李少琳[1] 方燕芬[1] 刘巧莲[1] 李淳南 

机构地区：[1]广东省潮州市潮安区庵埠华侨医院药剂科,515638 [2]广东省潮州市潮安区庵埠华侨医院呼吸内科,515638

出　　处：《国际中医中药杂志》2016年第6期512-514,共3页International Journal of Traditional Chinese Medicine

摘　　要：目的：探讨玉屏风胶囊联合舒利迭对咳嗽变异性哮喘（cough variant asthma, CVA）患者的免疫调节作用，评价临床疗效及安全性。方法将符合入选标准的CVA患者采用随机数字法分为2组各54例，舒利迭组吸入舒利迭，中药联合组在舒利迭组基础上加用玉屏风胶囊，均治疗12周。采用ELISA法检测 IL-17、IL-10、IL-6水平，评估患者咳嗽症状积分，评价临床疗效及不良反应发生率。结果治疗后，中药联合组 IL-17[（18.72±4.26）ng/ml 比（26.17±5.58）ng/ml，t＝2.462]、IL-6[（21.58±4.12）ng/ml比（30.66±6.27）ng/ml，t＝2.523]均较舒利迭组下降，IL-10[（15.56±2.74）ng/ml比（12.25±2.81）ng/ml，t＝2.244]较舒利迭组升高（P＜0.05）；中药联合组日间咳嗽积分[（1.12±0.26）分比（1.42±0.33）分，t＝2.283]，夜间咳嗽积分[（1.24±0.28）分比（1.52±0.37）分，t＝2.291]明显低于舒利迭组（P＜0.05）。中药联合组总有效率[92.6%（50/54）比77.8%（42/54），χ2＝2.438]明显高于舒利迭组（P＝0.037）。结论玉屏风胶囊联合舒利迭可减低CVA患者IL-17表达和升高IL-10表达，抑制气道高炎症反应。Objective To detect the immunoregulation and clinical effect ofYupingfeng capsule combined with Seretide on patients with cough variant asthma （CVA）.Methods CVA Patients were randomly divided into the Seretide control group （n=54） andYupingfeng capsule combined with Seretide group （n=54）. Seretide group received inhaled Seretide. Combined traditional Chinese medicine group received Seretide and Yuping Feng capsule. Two groups were treated for 12 weeks. The IL-17, IL-10 and IL-6 expression was detected by ELISA analysis. The clinic effect rate and adverse events were compared.Results After treatment, compared with the Seretide group, the expression of IL-17 （18.72 ± 4.26 ng/mlvs. 26.17 ± 5.58 ng/ml;t=2.462,P〈0.05） and IL-6 （21.58 ± 4.12 ng/mlvs. 30.66 ± 6.27 ng/ml;t=2.523,P〈0.05） were significantly lower in combined traditional Chinese medicine group than that in Seretide group; and IL-10 （15.56 ± 2.74 ng/mlvs. 12.25 ± 2.81 ng/ml;t=2.244, P〈0.05） was significantly higher in combined traditional Chinese medicine group. The daytime （1.12 ± 0.26 vs.1.42 ± 0.33,t=2.283） and night time cough score （1.24 ± 0.28vs. 1.52 ± 0.37,t=2.291） in combined traditional Chinese medicine group was significantly lower than that in Seretide group （P〈0.05）. The clinic effect rate （92.6%vs. 77.8%,χ2=2.438） in combined traditional Chinese medicine group was significantly higher than that in Seretide group （P=0.037）.ConclusionYupingfengcapsule combined with Seretide can decrease IL-17 expression and increase IL-10 expression to inhibit inflammatory reaction in CVA patients, and showed significantly higher clinical effect rates.

关 键 词：哮喘 玉屏风胶囊 舒利迭 免疫调节 治疗结果 

分 类 号：R562.25[医药卫生—呼吸系统]